Good afternoon, and thank you for joining us today to discuss OptimizeRx Corp. Third Quarter Ended September 30, 2019. With us today is the Company's Chief Executive Officer, William Febbo; and the Company's President, Miriam Paramore. They are joined by the Company's Chief Financial Officer, Doug Baker; and Chief Commercial Officer, Stephen Silvestro. Following their remarks today, we'll open the call to questions. Then before we conclude today's call, provide some important cautions regarding the forward-looking statements made by management during the call. I'd like to remind everyone that today's call is being recorded and will be made available for telephone replay via instructions in today's press release in the Investors section of the company's website. Now I'd like to turn the call over to OptimizeRx CEO, William Febbo. Please go ahead, sir.

Thank you, and good afternoon, everyone. Thanks for joining us today. During the third quarter, we made broad advances with our digital health platform, scaling it beyond pharma with the relevant set of solutions designed to assure greater adherence, affordability and patient engagement. As you saw in the press release we issued earlier today, we experienced a rare setback in year-over-year revenue growth. This was primarily due to the confluence of 2 unusual events involving three of our larger clients. First, one of our clients decided to stop supporting one of the brands about 12 months prior to their loss of exclusivity coming up in 2020, which in our experience was earlier than usual. The loss of this brand represented about $2 million in annual revenue or less than 10% of our revenue for the year. However, we believe we have a solid relationship with this client and have visibility in the future business with new brands they'll be introducing. We also have more than 20 other brands, which have increased their year-over-year budget and are looking to grow considerably into 2020. Steve will talk to this more later in the call. I should also mention that we have been diversifying our revenue stream over the course of the last year, both internally and through acquisition, and we expect this to lessen the impact of any similar future event. Secondly, the merger of 2 of our larger clients, which is now complete, pushed out about $3 million in revenue from the second half of '19 into 2020. There were initial indications this wouldn't happen, but it is now clear the revenue will go into next year. While in the past, we have successfully navigated similar risk factors, the timing of this one was unfortunately out of our control. The good…

Thanks, Will, and good afternoon, everyone. Earlier today, we issued a press release with the results of our third quarter, which ended September 30, 2019. A copy is available for viewing and may be downloaded from the Investor Relations section of our website. We also filed our 10-Q this afternoon as well. For the second quarter of 2019, our total revenue decreased about $400,000 to $5 million primarily due to the client events Will discussed. Despite the decrease in revenue, we maintained a gross margin of 60.4%, which was up from 58.1% in the year ago quarter. The improvement was due to a favorable shift in product mix. We expect to continue to maintain gross margins of at least 60% on a quarterly basis. Our operating expenses totaled $5 million, up from $2.9 million in the same year ago quarter. This increase was due to additional expenses related to our growth initiatives, including our acquisition of CareSpeak Communications in October 2018 and other new hires in the last year. Approximately $1.1 million of expenses related to our recent acquisition of RMDY Health and research related to potential new product offerings is also included in the quarter. There will be similar expenses in the fourth quarter but these type of expenses are not expected to occur on an ongoing basis. We continue to watch our expenses closely. For the third quarter, our bottom line on a GAAP basis was a net loss of $1.6 million or $0.11 per share. This compares to net income of $245,000 or $0.02 per share in the third quarter of 2018. While we expect to remain cash flow positive and return to GAAP profitability on a quarterly basis, onetime expenses related to investments and growth initiatives or noncash charges could result in a GAAP loss in…

Thanks Doug. Now with what we view as a temporary revenue shortfall behind us, I hope to convey our strong optimism around our future, both immediate and long term. Looking first at the numbers. Our aggregate pipeline, which is comprised of outstanding RFPs we've submitted, is showing a 50% increase over last year and sits today at around $70 million. For such RFPs, we have historically achieved a 35% to 50% close rate. In addition to the significant pipeline growth, we have five enterprise deals totaling $30 million, which we're currently reviewing with our clients. These deals, while in early stages, address the need for a holistic solution set for improving adherence, which we are all well positioned to deliver on. We believe there will be more to come as we progress these initiatives. Our commercial organization has really come together nicely in the past couple of months such that we're able to address the increasing demands of our core customers within the pharma industry and service our new client segments of payers, medtech and medical associations. Our team and client expansion aligns with our passion for improving adherence and ultimately, better outcomes for patients. We're also witnessing an accelerated migration to digital solutions by pharma with an augmented focus on patient experience specifically. Manufacturers are anxious to link key puzzle pieces of the care continuum together to provide added clarity and empower physicians with the tools they need to help their patients. This move aligns with our unique ability to reach and educate physicians at the point of care, so they can have more informed conversations with their patients about treatment options. Every patient presents a unique challenge and OptimizeRx has the tools and solutions to help our pharma customers and the physicians in the network to navigate these…

Thanks Steve. I'd like to address three important topics today: first, backing up a little bit is the strategy that Will talked about before. This drives our product portfolio and why it matters. Second, a major win we recently had through our new exclusive agreement with NewCrop and the launch of our Innovation Lab. And lastly, how RMDY will help us drive revenue and profitability as a new important segment of our platform. Regarding strategy first. As our business strategy grows and changes, so does our portfolio of solutions. Earlier this year, we made a strategic decision to enter the payer market and the acquisition of RMDY gives us some powerful tools to meet their needs, particularly in the areas of digital care management and digital member engagement. Steve has already talked about how our portfolio of solutions matches the needs of the pharma sector. I'd like to expand on how a strategically orchestrated portfolio of solutions can meet both pharma and payer needs. OptimizeRx was built on the value we create for pharma through our EHR network, the value of aggregation for those in the health care ecosystem who want to communicate digitally with providers at the point of care. We have created a successful business by "lighting up" this network for use by the pharma sector. We believe we can do the same with the payer sector. Payers also want to communicate with the point-of-care to help improve their relationships with the health care providers and to support their members' health journeys. Our OPRX EHR network is now only one part of our unified cloud-based platform. Leveraging our EHR network and the cloud to support both the pharma and payer sectors can yield tremendous economy of scale. Leveraging our platform across multiple market sectors shows how we are…

Thanks Miriam, Doug and Steve. As we look ahead, it's clear we are addressing a large market with a significant penetration opportunity. And as you heard from Steve and Miriam, our digital health platform addresses many pain points for all involved. In order to grow our market share, we are focused intently on expanding revenue by client and reaching new client segments. We are also working to expand our solution set, EHR network and strategic partnerships. With our acquisitions of CareSpeak and RMDY, we have expanded our total addressable market by severalfold, adding digital care and health management to our solution set. So we're not only better able to address our existing HCP messaging market, which is estimated at more than $2.4 billion, but now the patient engagement market, digital therapeutics and care management. This brings our total addressable market to north of $48 billion. This means we see a lot of room for growth ahead in this year and beyond and as we continue to attract and retain the most capable team to size this opportunity and take advantage of it. We're very excited about the future. Our EHR and e-prescribing platform currently reaches most of the EHRs that enable messaging within point of care. Our success in acquiring, integrating and expanding into new EHR, eRx platforms continues to grow. We view them as our partners. We deliver needed content to their members and ultimately, revenue to their businesses. We're very proud of our channel network and appreciate everything they do for the health care ecosphere. Over time, they will need to innovate with us, and we are proud that NewCrop selected us as their preferred partner, as Allscripts or Veradigm did many years ago. We continue to enjoy tremendous market opportunity being perfectly positioned between all the stakeholders…

[Operator Instructions] We'll hear first today from Andrew D'Silva with B. Riley FBR.

Doug, real quick, just from you. If you could just explain the $280,000 benefit related to the earnouts from CareSpeak. Any color on why there was a clawback there. And then while you're pulling that still, if you could provide a little color the customer that left earlier, at least as it relates to the brand. Like what was the rationale that they gave you? Was it just too much cost in their space? [Technical Difficulty] or was there any client traceability issues that we should be thinking about?

So your question about the CareSpeak earnout, there's a GAAP fair value calculation has to be done and it's based on future projections. We lowered our projections for 2020, specifically related to CareSpeak or that product line a little bit. We still expect them to make their whole earnout, but that's not the way GAAP works. So...

A good GAAP management. This is Will. On the second question, the penetration of market was so great that they decided they just didn't need to continue to spend on it. That's ultimately the case. And while disappointed, it's their call. And we still have a very good relationship with that client and expect revenue to increase into next year compared to this year.

And there were some client reporting issues that happened - well, not related to - not caused by anything. Again, just something macro in the market. And I was curious if any of those three customers that had kind of that anomaly in the third quarter. Or that customer, as far as I believe, you were kind of allocating some Q1 benefits back into the back half of the year.

Yes. No, that was a temporary, basically a reporting requirement that we were able to address, hasn't been an issue through the year. This was strictly an isolated patent expiration issue, just stopped spending early, unfortunately.

And then as it relates to RMDY Health, can - and you gave really good color on the market there. I'm just curious to get a little insight into how it's differentiated from Livongo as far being - and will it be actually included in enterprise package as well?

I can start and then maybe Miriam could add. So the differentiation from Livongo is basically is Livongo is specific content, specific method to enable adherence-related activities. And so you buy into their way, which is very impressive and very effective as they show. It's a great business. We bought RMDY because it basically can enable anyone to do anything they want with health care and it focused on adherence. And so you can almost think of it like a Wix for health care. It's just a very easy way to - in a SaaS model, allows someone with content and members to enable them digitally. And there are - they're obviously the very big players, and then there's a big middle market that has - that are all desperate to be digital because their members now are requiring it, and we think that's a great opportunity for RMDY.

Andy, this is Miriam. I'll weigh in just a little bit. So Livongo took also a disease-specific approach. So they took a combined sort of hardware and content approach. They actually created their own devices and started from the hardware side before they went into the content and the services side. So they're a combined technology and services company with diabetic nurse educators on the back end. Our strategy is to stay a focused technology company and not to include back end call centers and things like that. So that's a point of differentiation. But broadly speaking, the solutions are trying to help ease the pain of care management or disease management and use digital technology, current contemporary technology to do that. So the last thing I would say is that our solution set is not disease specific. It is not therapeutic area specific. It can be used for any and the focus is more about enabling an organization, whether that be a payer or pharma who has clinical pathways and a bunch of content that's research-driven that already exists, but it's offered up via phone or coaching advice or acceleration to move that into contemporary technology communications.

We'll hear from Richard Baldry with ROTH Capital.

I'm kind of curious if you could talk about what typical contracts look like with brands. I guess I'm surprised that midyear someone can drop out sort of or alter their spending pattern so quickly. So are there not minimums involved or at certain price points for volumes, guarantees. Or is it very optional for the customers on the fly to change their spend pattern?

Thanks for the question, Richard. Typically, the agreements that we've got are 12-month agreements. They - we will open an SOW, and then revenue is recognized as we deliver on that revenue throughout the year. So in the case of an LOE and client pulling back, basically they move that brand out. There was not a guarantee in that specific agreement to be able to have significant clawback to replace that revenue. And so that's the impact that we felt. And going forward, we've adjusted in our contracting language to account for that. Also Will sort of alluded to the recurring revenue model, which is a little bit of a switch from the model that we've had in the past as far as remuneration of contracts, et cetera. So we're preventing that sort of revenue clawback issue from occurring and the revenue drop out. Makes sense?

Yes. And when you talk about the revenues pushing out of the second half of '19 into 2020, does that mean that you think that, that spend will be incremental to what you otherwise would have expected from those clients in 2020? Or is it really sort of it delays the beginning of that climb into a later period?

Well, I'll let Steve answer as well. But I - it's - now that, that is a gigantic company, we view it as nothing but upside. They have so many needs. We are at the table. Often when these things happen, you actually gain a little bit more relationship because they actually want to do the work and for their own reasons can't. So you stay close to it and in staying close and having a broader footprint in terms of brands and disease areas, we think that's going to be a terrific opportunity for us.

Yes, totally agree. It will be upside opportunity on the year from what we would initially have anticipated.

Given enthusiasm around the additional head count you put in commercial side, can you talk about whether you think you'd continue to add to that head count sort of early in 2020 or entering the year? Or you feel like the team you have right now should gel a bit more before you add on top of it?

I think we're - we will continue to add as we need to add, Richard. So what we will - what we have done a good job of is bringing the right people in at the right time, getting them ramped, trained, letting them prove out their worth in the market and then adding as we go. What we don't want to do, which is what you're alluding to, is just adding heads for the sake of adding head count. I think we're very disciplined about that. So when we have the correct people to bring on board, we execute, bring them on board when the opportunity is there. Outside of that, we're continually scoping and looking for new talent and continue to bring people in, as is necessary, but not on prematurely.

Okay. And I'm not sure if you'd be willing to answer this, but when you talk about expecting strong growth in the fourth quarter year-over-year, if I look at the last 4 quarters, growth has ranged anywhere from, putting the third quarter aside, growth range anywhere from 27% to 75%. So there's a lot of room there. Now that we've seen that revenues can swing pretty meaningfully, is there any way to kind of gauge and then narrow that band down on what you'd expect in the fourth quarter maybe versus any of your prior periods?

Yes. Thanks, Richard. Yes, it's tough because we obviously don't give guidance, so it's a little tricky. But I think if you go back and look at earnings calls, yes, as everyone who knows me knows, I'm consistent. And I try not to be emotional on these, so that you actually believe me. And I think if you go back and look at what we've referred to as strong, you'll be able to get a good range. We obviously wouldn't say that lightly because the last thing you want to do as a company is disappoint twice in a row. And so we feel really good about it. The team is humming, our morale is high. We really run the company not around the quarterly calls. We run it around our clients. And that's really important. We are disappointed. We're not hiding from it. We're right in front of it, but feel really good about the next quarter and frankly, 2020 as well.

And from William Blair, we'll move to Ryan Daniels.

Will, maybe one for you, a follow-up on Q4. At this point, how visible is your revenue stream for the fourth quarter versus how much you need to kind of go get or see clients flushing through some year-end budget. So what's the visibility to your internal target at this point?

The visibility on the internal target is good. It will be better in 20 days because you get a lot of upsell opportunity in end of November, early December. We are ready for it. We're already seeing some of it. Success often begets success. And our clients don't watch our quarterly calls. They're meaningless to them. They really deliver. They're really about all our service and there we're doing a great job. So I feel pretty good about the Q4. Obviously, we have some new businesses. We're still learning visibility on those. But because they are more recurring in nature, there is good visibility there. We talked about it, Ryan, it's when we came in, we had no visibility then we felt like we had a quarter and we got to about 6 months. You can still have disruption. We've talked about these risk factors. And we're working really hard on getting rid of those risk factors. But it's going to take time. But just to answer directly your question, we have pretty good visibility on Q4.

Okay. That's very helpful. And then if we look at the revenue hiccup in the quarter, especially as it relates to the merger between the 2 entities, the larger dollar item. Is that a contract where you are just hoping that the larger organization needs to kind of engage more third-party help? Or have you actually had the contractual agreements or seen RFPs, which indicates that this is definitely just a blip or a transitory/timing issue versus something that could extend into 2020.

Yes. So I'll take that one, Ryan. This is Steve. So we actually do have the RFPs that we've responded to. In addition to sort of this revenue blip of the merger, that specific company, one of the clients had a drug recall, which added to sort of the near-term pain. And so it really caused them to pause and focus on that recall and executing it effectively. So the RFPs were paused, but we have those RFPs and receipt and we're progressing those along very nicely. So as Will said, I do believe it's a pause, not a close.

And then last question and I'll hop off. If we think of the $70 million in the pipeline and the typical close rate, 35% to 50%, how much of that could actually flush into 2020 sales? So just, let's say, we use basic math, $70 million, 50% is $35 million, how much of that if it's signed this year would actually go into 2020 sales versus being something that might be a multiyear contract? How should we view that metric you just gave us?

Yes. It's a great question. I'll try not to provide any guidance on answering the question. But essentially, we - the $70 million represents opportunities created in the period versus $30-some-odd million from previous year, which were opportunities created previous year. So some of those will push into 2020, no question. I think we've got great runway rather on having a good opening position for 2020, which is what we are laser-focused on in addition to executing a great Q4. That's really sort of at the heart of building one of these businesses and scaling it to where we are trying to track. So hopefully, that - in a roundabout way, answers your question without providing specific guidance.

We'll hear now from Bruce Goldfarb with Lake Street Capital Markets.

Miriam, Steve, Will, Doug, congrats on all your progress and success. Just have a couple of questions. You previously mentioned the potential for broader enterprise engagements with your pharma customers. Can you give us any update on how these discussions are progressing?

Yes, happy to. This is Steve. We've got several, and by several, we're progressing 5 really key deals right now that are - I would say, they're in mid-stages, mid- to late stages, comprised of multiple solutions across our platform set, which is really what we're driving toward. I don't know how much more you want to hear about as of now but that's…

At least the ones that you talked about earlier, the - around - so you quantified maybe around $30 million, are those different?

Those are done. Yes, those are done.

Yes. And I think just to clarify because we talked about a little bit of Q2 when I got subsequent conversations with investor. By enterprise, that's really defined by taking our either complete solution set and bringing it to a brand or taking multiple brands around a specific solution and dominating that. And it just gives you the opportunity to engage in a deeper level with the client. It's a bigger engagement. And it's really tied to the impact of that overall solution set. So we'll keep defining that over time, but it's really important to get above the tactical selling. We still do it but you can't just jump to it overnight. But it's really what our client prefers because it's more meaningful.

And then just to give you an example, one customer this year, we've got basically an enterprise situation. Last year, they did full year revenues of $774 million. This year, they're going to be just about $4 million. So that gives you an idea of scale.

Yes. That's why it's important.

And then you mentioned on the call that an option M&A is something you're considering. Are there certain capabilities or things you're sort of targeting that you'd like to add to the portfolio?

We have a pretty tight screen on what we're going to look at. So anything that would expand reach to HCPs for patient, any kind of solution set that could get us connected to pharmacy and then any kind of digital enablement of communication that either doesn't have access to pharma or to payers but they have technology. So we're really focused on the 2 we have right now and becoming one company and doing it, I think, a very good job of that with Miriam leading the way. But that's our screen. We're going to stay pretty - we're going to stay in those guardrails.

We'll move on to Josh Goldberg with G2.

I had a couple of quick questions and I appreciate the thoroughness of the call. And Steve, welcome. I guess I'll start by just asking, obviously your business is a advertising German business that the budgets can change pretty quickly as we've seen in this quarter. It seems to me like you're trying to get some more visibility into next year by some of these enterprise contracts if they sort of grab bag of orders that you might get which is probably what gives you less visibility in '19 than what you might have in '20. The pipeline as well looks exciting. So I guess it seems like a lot of advertising, interim advertising in health care. Generally, you get a better sense sort of January time frame. Do you have any sense from us based on the pipeline or based on your conversations that comment about 25 to 50 or 70 of your business, the pipeline coming through? I mean you're implying a nice growth next year. Can you give us any sort of comments or commentary that could give us confidence that we're looking at a growth here?

Yes, I think - thanks, Josh. Good question. And two things I'd like to say, and then maybe, Steve, if you want to jump in, you can. We've got a ton of credibility right now with our client set. And I think that, that is very meaningful in pharma. I was always asked 2 years ago, well, why aren't you a $100 million company. And then a year ago, why aren't you a $150 million. And it's because pharma doesn't move fast. You have to prove yourself. You have to have measurement of that proof. And then I would say the second point, and we've done that, I think we've done that with the best manufacturers you can do it with. So we have just a great, solid base. The second is, and Steve can talk to this more, is we've repositioned how we're selling to our client in a way that is in their language, it's more meaningful to their pain points, but it's the same solution set. So as investors, you don't have to worry about we're going and creating new stuff. We're just delivering it in a different way that connects into their thought process, their budget cycle. And my hats off to Steve and the sales team because we've really brought that into this business. And I think it's significantly changing our profile.

Yes. I mean just to add, Josh, just around the question around visibility specifically into January. I mean the way that our contracts work and the way that we sell, right, we sell a contract, we open up a PO and then revenue is recognized as we distribute over the months, right? So we have fairly good visibility into 2020 based on the sales that we will make in the fourth quarter, which will not be revenue recognized sales for 2020, but the revenue will start to drop in Q1 of next year, starting in January. So our - we've now got in our business, developed forward-looking revenue metrics to help us guide and orient the business in a more meaningful way.

Let me just add one thing. This is Miriam. That don't forget our supply side win, we have a huge, huge advantage with NewCrop. And our competitors can't sell in there. So that market share is shifting period.

All of it.

All of it. And so it's - that by itself has - is a huge driver of growth for next year.

Is that helpful, Josh?

Yes. Do you think that having enterprise contracts also is something that will give us better visibility and the fact that this NewCrop opportunity gives you more supply will kind of catalyze that? Or we're still going to kind of walk through 12 months from now and still have a sense of what the fourth quarter might or might not be if you think we'll have better visibility 9 to 12 months from now for next year?

Yes. I mean that is the reason for the enterprise push, right, is to develop more predictive revenue streams. So when you think about what we're doing there, I think, number one, it enables us to do a 12-month contract, right, instead of short term or transactional stuff, as Will has said and you've heard him say. Also allows us to enter into now multiyear agreements, which we've got a couple in the pipeline right now, including some of those enterprise deals. So that's really an opportunity for us to actually be very predictive around our revenue and build that recurring model that you've been hearing us talk about.

And in addition, the RMDY revenue - historical RMDY revenue is SaaS-based revenue, highly predictable. So once - as that revenue builds that just increases visibility as well. So those are 3 kind of factors: multiyear, NewCrop supply control and SaaS-based recurring that improve our predictability.

Our next question will be from Ron Chez, a Private Investor.

I have a couple of quick questions and then a longer one. How much of the expense increase in the third quarter was nonrecurring. I wrote down $1.1 million. Am I right about that, Doug?

You are. Correct. That's the number.

So expenses would have - without these things, would have been lower by $1.1 million, correct?

Correct.

And what is the NewCrop advantage? It's another set of physicians, HCPs. Is that it? I mean I know exclusive, but how is that different how is that different than some other EHR capability?

Ron, this is Miriam. I'll take that. First of all, exclusivity is the biggest is the lead - the headline and the subheadline. But the Innovation Lab is really the growth engine, if you will, for expansion and new monetization so we have an established EHR network that's the largest EHR network, digital EHR communication network in the marketplace. And we're monetizing that with pharma. We're also going to monetize that with payers. But within pharma, we're going to find new ways to monetize the same railroad track through this Innovation Lab. We have a couple of pilots that we are finishing the design element on right now within that hotbed of 65,000 providers. And so we're going to prove in those pilots value creation. And once we prove value creation inside of NewCrop because they've agreed to incubate with us, then we can look to expand and scale that to multiple EHRs, multiple e-prescribing. But you have to have a place to start to show that you're creating value and there's ongoing revenue go get. So that's - different.

NewCrop delivers what, 65,000 HCPs?

They do.

That you're going to sell? Are they going to be sold financial messaging, brand messaging? You're going to sell into there?

So we don't sell into our EHR channels. They are our partners. So we have business-to-business agreements with the EHR channel and we light up as many types of messages for commerce as we can with them. So with the example of NewCrop, we can do all 3 of the messaging types that drive our revenue. And then - so we're going to fill up all of those - that pipe with all of those messages that we can get from pharma in the traditional business sense of OptimizeRx. But we're also going to incubate and find new types of digital commerce to drive from pharma to NewCrop and from - to NewCrop users and from payers to NewCrop through this lab environment. So it's just that, that beautiful utilization as much traffic as you can over the same type and monetize every piece of traffic.

I'll ask a question about that offline, okay?

Okay.

Did you ever mention RMDY's run rate?

We did not. No.

And is it what you expect it to be right now? I mean - there's - initial assumption you have?

Yes. We're a couple of weeks in. We see a lot of opportunity there. It's primarily on the payer wellness, medtech side, all very good clients that have returned. So we expect to be able to continue to grow that. And I think there's also an ability to introduce this delivery to pharma at a certain stage or prelaunch stage. So yes, we feel good about the team is excellent, and it really adds a lot of muscle to our company from a technology standpoint.

Without seeing what their sales have been or would be this year, do you expect, however you define that, do you expect explosive growth from RMDY? Explosive to me is between 50% and 100% next year.

Yes.

The answer is yes?

The answer is yes.

And this is the longer question. Steve, you touched on this. If you can - well, maybe it's the client that you were talking about without name, that client was how much in '18 that in '19 is $4 million?

Yes. So in '18 full year, they were 7 74 then full year 2019, they're going to be close to $4 million.

And is that because of additional brands?

More several - it's additional brands coming on and additional solutions per brand. So if you think about sort of - traditionally, we had started out with financial messaging. We've now commercialized new solutions like brand messaging, clinical messaging, et cetera. Will it represent enterprise suite of solutions, Ron, and that's the growth that we've chatted about on other calls.

One more question attending to that. So you said 7 74 and $4 million, what's a ballpark expectation for growth into '20, same client?

Same client? I think probably between, I'd say, between 6 and 7 is a good number.

Okay. Are there other clients...

So that's just giving you...

You guys - clients like that?

Yes, there are multiple, as I mentioned earlier, there are multiple late stage or midstage enterprise deals that are representative of that same sort of pattern we see when buying those enterprise deals across the solution set.

So you expect that revenue to grow whatever in ballpark, and that's as a result of enterprise solutions being provided with the various delivery of the components that you have?

It's a direct result of that, yes.

And at this time, I'd like to turn things back to Mr. Febbo for any closing remarks.

Thanks to everyone for joining the call. We had actually a record number of people, which is wonderful. If you could take just one thing away from our discussion I hope it's the understanding of our potential for continued strong growth, while generating tremendous value for everybody. And beyond the numbers, I hope you see that we're really creating a unique corporate culture dedicated to something that matters in health care, very topical, makes a difference in people's lives from patients to physicians and beyond. When we can grow at these levels, and I will highlight that we're still on a very good growth rate for this year, it's always disappointing to see a quarter that's not what you want it to be. It's also for our team a kick towards even being more aggressive. And we've got a team that is capable for scaling this business to a very, very large business. And I think all that combined translates into a great opportunity for our stakeholders, and I hope you all agree. Have a good night, and I look forward to talking to you all. Take care.

And ladies and gentlemen, now before we conclude today's call, I'd like to report the company's safe harbor statement that includes important cautions regarding forward-looking statements made during today's call. Statements made by management during today's call may contain forward-looking statements within the definition of Section 27A in the Securities Act of 1933 as amended and Section 21E at the Securities Act of 1934 as amended. These forward-looking statements should not be used to make an investment decision. The words anticipate, estimate, expect, possible and seeking and similar expressions identify forward-looking statements, and they speak only to the date that statements were made. Such forward-looking statements in this presentation include statements regarding estimation of total addressable market size, market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology, investments, growth opportunities, acquisitions, upcoming announcements and the need for raising additional capital. They also include the management's expectations for the rest of the year and adoption of the company's digital health platform. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from these set forth and are contemplated by underlying forward-looking statements. Risks and uncertainties to which forward-looking statements are subject to could affect business and financial results are included in the company's annual report on Form 10-K for the fiscal year ended December 31, 2018. This form is available on the company's website and on the SEC website at sec.gov. Before we end today's conference, I'd like to remind everyone that this call will be available for replay starting later this evening and running through November 26. Please refer to today's press release for dial-in replay instructions available via the company's website at www.optimizerx.com. Thank you for joining us today. That concludes today's conference. You may now disconnect.